Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended			12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012		Dec. 31, 2012
Operating Activities:
Net loss	$ (2,413,050)	$ (7,572,110)		$ (9,999,599)
Less: Loss from discontinued operations, net of tax		(4,736,786)	[1]
Loss from continuing operations	(2,413,050)	(2,835,324)
Depreciation and amortization	199,220	758,157
Amortization of debt discount from investor warrants	70,364	98,831
Stock issued for services		97,499
Financing costs	37,000
Loss on write-down of notes receivable	593,437
Realized gain on trading securities	(253,419)
Loss (gain) on sale and impairment of equity and available-for-sale securities	70,148	(47,630)
Gain on derivative liabilities	(35,842)
Fixed asset impairment	450,000
Stock-based compensation	129,691	262,767
Other	204	52,036
Changes in operating assets and liabilities:
Accounts receivable	70,716	(15,292)
Prepaid expenses and other assets	86,248	9,644
Deferred revenue	(43,465)	35,600
Accounts payable and accrued expenses	325,850	422,963
Net cash flows from operating activities of continuing operations	(712,898)	(1,160,749)
Investing Activities:
Payments on notes receivable	475,000
Capital expenditures	(60,395)	(661)
Capitalization of software development costs		(45,525)
Proceeds from disposal of business		600,000
Proceeds from sale of securities	322,987	63,903
Net cash flows from investing activities of continuing operations	737,592	617,717
Financing Activities:
Net proceeds from stock offering		223,286
Proceeds from line of credit	240,000
Proceeds from debt financing	75,000
Payments on long-term debt	(398,685)	(457,909)
Net cash flows from financing activities of continuing operations	(83,685)	(234,623)
Net cash flows from continuing operations	(58,991)	(777,655)
Net cash flows from discontinued operations		823,272
(Decrease) Increase in cash	(58,991)	45,617
Cash at beginning of period	75,910	268,170		268,170
Cash at end of period	16,919	313,787		75,910
The Company disposed of its Pharmalicensing, Global Licensing, Pharma Transfer and Knowledge Express operating divisions. In conjunction with the disposal, the Company received the following consideration:
Total sale price		2,000,000
Debt discount recorded	121,500
Unrealized gain (loss) from available-for-sale securities	(3,574)	(33,523)
Supplemental Disclosures of Cash Flow Information
Cash paid for taxes	0	0
Cash paid for interest	228,017	398,213
Note Receivable Received [Member]
The Company disposed of its Pharmalicensing, Global Licensing, Pharma Transfer and Knowledge Express operating divisions. In conjunction with the disposal, the Company received the following consideration:
		1,329,670
Liabilities Assumed [Member]
The Company disposed of its Pharmalicensing, Global Licensing, Pharma Transfer and Knowledge Express operating divisions. In conjunction with the disposal, the Company received the following consideration:
		$ 70,330

[1] The Company recognized a $4,756,898 impairment loss for the strategic services business segment during the nine months ended September 30, 2012.